Clinical Trials Browser

Leukemia, Myelogenous, Chronic, BCR-ABL Positive × asciminib × 90 days × Clear all

Leukemia, Myeloid, Leukemia, Myelogenous, Chronic, BCR-ABL Positive, Leukemia, Myeloid, Chronic-Phase

NCT05413915 2026-05-29

Asciminib Used in Consolidation With Imatinib vs. Imatinib to Achieve TFR in CP-CML

Phase 3 Terminated

8 enrolled

MyeloidOther hematologic neoplasm

Leukemia, Myelogenous, Chronic, BCR-ABL Positive

NCT06092879 2026-05-29

ASSURE-3

Active not recruiting

201 enrolled

MyeloidOther hematologic neoplasm

Leukemia, Myelogenous, Chronic, BCR-ABL Positive

NCT05456191 2026-05-27

ASC4START

Phase 3 Active not recruiting

568 enrolled 11 charts

MyeloidOther hematologic neoplasm

Leukemia, Myeloproliferative Disorders, Philadelphia Chromosome, Leukemia, Myelogenous, Chronic, BCR-ABL Positive

NCT07354074 2026-05-26

Study to Determine the Efficacy and Safety of Asciminib in Pediatric Patients With Ph+ CML-CP

Phase 2 Recruiting

50 enrolled

MyeloidOther hematologic neoplasm

Bronchiolitis Obliterans Syndrome, Leukemia, Leukemia, Myelogenous, Chronic, BCR-ABL Positive

NCT06236724 2026-05-15

Phase II Study Assessing Efficacy and Safety of Asciminib in Patients With Newly Diagnosed Chronic Myeloid Leukemia in Chronic Phase.

Phase 2 Recruiting

50 enrolled

MyeloidOther hematologic neoplasm

Leukemia, Myelogenous, Chronic, BCR-ABL Positive

NCT04877522 2026-05-11

Asciminib Roll-over Study

Phase 4 Recruiting

347 enrolled

MyeloidOther hematologic neoplasm

Blast Crisis, Myeloproliferative Disorders, Leukemia, Myelogenous, Chronic, BCR-ABL Positive

NCT04925479 2026-04-30

Study to Determine the Dose and Safety of Asciminib in Pediatric Patients With Chronic Myeloid Leukemia

Phase 1/2 Recruiting

34 enrolled

MyeloidOther hematologic neoplasm

Leukemia, Myelogenous, Chronic, BCR-ABL Positive

NCT03578367 2026-04-21

Study of Efficacy and Safety of Asciminib in Combination With Imatinib in Patients With Chronic Myeloid Leukemia in Chronic Phase (CML-CP) Who Have Been Previously Treated With Imatinib and Have Not Achieved Deep Molecular Response.

Phase 2 Completed

104 enrolled 33 charts

MyeloidOther hematologic neoplasm

Hematologic Diseases, Leukemia, Leukemia, Myeloid, Leukemia, Myelogenous, Chronic, BCR-ABL Positive

NCT06514534 2026-04-21

ASC4TARGET

Phase 2 Recruiting

20 enrolled

MyeloidOther hematologic neoplasm

Leukemia, Myelogenous, Chronic, BCR-ABL Positive

NCT05943522 2026-04-20

Asciminib RMP Study

Recruiting

600 enrolled

MyeloidOther hematologic neoplasm

Leukemia, Myelogenous, Chronic, BCR-ABL Positive

NCT06427811 2026-04-17

ASC4INDIA

Phase 4 Completed

85 enrolled

MyeloidOther hematologic neoplasm

Bronchiolitis Obliterans Syndrome, Leukemia, Myelogenous, Chronic, BCR-ABL Positive

NCT04971226 2026-04-06

A Study of Oral Asciminib Versus Other TKIs in Adult Patients With Newly Diagnosed Ph+ CML-CP

Phase 3 Active not recruiting

405 enrolled 18 charts 1 FDA

MyeloidOther hematologic neoplasm

Philadelphia Chromosome, Leukemia, Myelogenous, Chronic, BCR-ABL Positive

NCT03874858 2026-04-02

DANTE

Phase 2 Completed

124 enrolled

MyeloidOther hematologic neoplasm

Leukemia, Myelogenous, Chronic, BCR-ABL Positive, Leukemia, Myeloid, Chronic-Phase

NCT04948333 2026-03-18

Asciminib Treatment Optimization in ≥ 3rd Line CML-CP

Phase 3 Completed

199 enrolled 13 charts

MyeloidOther hematologic neoplasm

Leukemia, Myelogenous, Chronic, BCR-ABL Positive

Clinical Trials

ALERTCML

Asciminib Used in Consolidation With Imatinib vs. Imatinib to Achieve TFR in CP-CML

ASSURE-3

ASC4START

Study to Determine the Efficacy and Safety of Asciminib in Pediatric Patients With Ph+ CML-CP

Phase II Study Assessing Efficacy and Safety of Asciminib in Patients With Newly Diagnosed Chronic Myeloid Leukemia in Chronic Phase.

Asciminib Roll-over Study

Study to Determine the Dose and Safety of Asciminib in Pediatric Patients With Chronic Myeloid Leukemia

Study of Efficacy and Safety of Asciminib in Combination With Imatinib in Patients With Chronic Myeloid Leukemia in Chronic Phase (CML-CP) Who Have Been Previously Treated With Imatinib and Have Not Achieved Deep Molecular Response.

ASC4TARGET

Asciminib RMP Study

ASC4INDIA

A Study of Oral Asciminib Versus Other TKIs in Adult Patients With Newly Diagnosed Ph+ CML-CP

DANTE

Asciminib Treatment Optimization in ≥ 3rd Line CML-CP